TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05406739

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Test Meals
Description: For the first meal, Participants will be fasted for 8 hours and will consume a test meal of 255 calories (120 g egg substitute \[60 kcal\]; 2 slices of bread \[120 kcal\] with 30 g strawberry jam \[75 kcal\]; 72% carbohydrate, 24% protein, 2% fat, and 2% fiber) with 120 mL of water.~After five to seven days, participants will be fasted for 10 hours and will consume a second test meal of 510 calories (240 g egg substitute \[120 kcal\]; 4 slices of bread \[240 kcal\] with 60 g strawberry jam \[150 kcal\]; 72% carbohydrate, 24% protein, 2% fat, and 2% fiber) with 240 mL of water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Meals
Description: For the first meal, Participants will be fasted for 8 hours and will consume a test meal of 255 calories (120 g egg substitute \[60 kcal\]; 2 slices of bread \[120 kcal\] with 30 g strawberry jam \[75 kcal\]; 72% carbohydrate, 24% protein, 2% fat, and 2% fiber) with 120 mL of water.~After five to seven days, participants will be fasted for 10 hours and will consume a second test meal of 510 calories (240 g egg substitute \[120 kcal\]; 4 slices of bread \[240 kcal\] with 60 g strawberry jam \[150 kcal\]; 72% carbohydrate, 24% protein, 2% fat, and 2% fiber) with 240 mL of water.
Study: NCT06174012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Fluoride
Description: Sodium fluoride was applied before radiotherapy, at 3 months, 6 months, and 12 months after radiotherapy.
Study: NCT05805904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986278
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986278
Description: Specified dose on specified days.
Study: NCT05529134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTW-002 10 mg/g gel
Description: poloxamer hydrogel for topical administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo poloxamer hydrogel for topical administration
Study: NCT05956327

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aerobic Endurance Training
Description: Aerobic endurance training on a bicycle ergometer (week 1 to 6: three units per week á 40 minutes, week 7 to 12: three units á 45 minutes, in groups of up to three patients over 13 weeks)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flexibility, strengthening and balance training
Description: Flexibility, strengthening and balance training (exercises from the areas of stretching, strength, balance and relaxation, 3x40 min from week 1-2, 3x45 min from week 3-4 and 3x50 min from week 5-13, in groups of up to three patients over 13 weeks)
Study: NCT05805904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT05090631

Intervention type: GENETIC
Intervention: DNA analysis
Description: GWAS

Intervention type: GENETIC
Intervention: DNA analysis
Description: GWAS
Study: NCT05502094

Intervention type: OTHER
Intervention: Heart Rate Variability Measurement
Description: The heart rate variability of the participants will be measured with the Polar H10 device with a measurement time of 5 minutes.

Intervention type: OTHER
Intervention: Heart Rate Variability Measurement
Description: The heart rate variability of the participants will be measured with the Polar H10 device with a measurement time of 5 minutes.
Study: NCT05405569

Intervention type: OTHER
Intervention: CPR Arms Angle 90º
Description: Within each independent group, a randomized crossover design will be used: half of the group will start with arms position at 90º.

Intervention type: OTHER
Intervention: CPR Arms Angle 90º
Description: Within each independent group, a randomized crossover design will be used: half of the group will start with arms position at 90º.

Intervention type: OTHER
Intervention: CPR Arms Angle 90º
Description: Within each independent group, a randomized crossover design will be used: half of the group will start with arms position at 90º.

Intervention type: OTHER
Intervention: CPR Arms Angle 90º
Description: Within each independent group, a randomized crossover design will be used: half of the group will start with arms position at 90º.

Intervention type: OTHER
Intervention: CPR Arms Angle 60º
Description: Within each independent group, a randomized crossover design will be used: half of the group will start with arms position at 60º.

Intervention type: OTHER
Intervention: CPR Arms Angle 60º
Description: Within each independent group, a randomized crossover design will be used: half of the group will start with arms position at 60º.

Intervention type: OTHER
Intervention: CPR Arms Angle 60º
Description: Within each independent group, a randomized crossover design will be used: half of the group will start with arms position at 60º.

Intervention type: OTHER
Intervention: CPR Arms Angle 60º
Description: Within each independent group, a randomized crossover design will be used: half of the group will start with arms position at 60º.
Study: NCT05699044

Intervention type: DIAGNOSTIC_TEST
Intervention: Amyloidosis screening (bloodtest, DPD-scintigraphy, potentially endomyocardial biopsy)
Description: Bloodtest: Troponin I, NT-pro-BNP, electrolyte status, renal function, kampda/lambda free chain + ratio, M-komponent.~DPD-scintigraphy. (Echocardiography)
Study: NCT05502094

Intervention type: OTHER
Intervention: Heart Rate Variability Measurement
Description: The heart rate variability of the participants will be measured with the Polar H10 device with a measurement time of 5 minutes.
Study: NCT04741204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Extended Release Oral Tablet
Description: initial dose of metformin of 750 mg Q.D. (with dinner) for 3-4 weeks. They then will be increased to the final dose of 750 mg BID (breakfast and dinner) until the end of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Extended Release Oral Tablet
Description: initial dose of metformin of 750 mg Q.D. (with dinner) for 3-4 weeks. They then will be increased to the final dose of 750 mg BID (breakfast and dinner) until the end of the study.
Study: NCT06290531

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buzzy device (cold and vibration)
Description: The device produces cold and vibration to act on the gate control theory and provide painless injection by nerve distraction

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buzzy device (vibration only)
Description: The device produces vibration to act on the gate control theory and provide painless injection by nerve distraction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: precooling
Description: Ice cubes used for applying coolness at the injection area
Study: NCT06038695

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xenogeneic Volume-Stable Collagen (VCMX) graft with growth factor-BB
Description: * Fibro-Gide is the Volume-Stable Collagen Matrix.~* Recombinant human platelet-derived growth factor-BB will be found within the device of GEM21S.
Study: NCT05652075

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pericapsular nerve group and lateral femoral cutaneous nerve block
Description: Will undergo pericapsular nerve group block (PENG) combined with lateral femoral cutaneous nerve under ultrasound guided block with 20 mL of 0.25% bupivacaine.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lumbar plexus block
Description: Will undergo Lumbar plexus block (LPB) under ultrasound guided block with 20 mL of 0.25 % bupivacaine.
Study: NCT06463249

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CORE Helpline
Description: All participants will receive the Core Helpline program (CORE) for 2 months, which includes written weight loss material, use of a smartphone app, weekly text messages and email reminders and 1 optional participant-initiated coaching call per month.
Study: NCT06089434

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transesophageal Echocardiography (TEE) with limited number of TEE clips
Description: The intervention group would be limited to fewer than 20 TEE clips per case (versus the average of \~ 80-100 TEE clips per case).

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Transesophageal Echocardiography (TEE) with number of TEE clips per attending anesthesiologist
Description: The control group would leave the number of TEE clips to the discretion of the attending anesthesiologist.
Study: NCT05795556

Intervention type: OTHER
Intervention: Assessing sarcopenia and potential biomarkers of sarcopenia in fall patients
Description: Blood test, body composition (BIA and/or DXA), balance tests (sway), handgrip strength, isometric knee extension strength, chair-rise test, gait-speed, thickness of the thigh muscles (ultrasound), screening for sarcopenia (SARC-F), screening for malnutrition (SNAQ), screening for depression (GDS-15), screening for self-rated health (EQ-5D-5L), frailty (CSHA Frailty Scale)
Study: NCT06170723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986368
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986368
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986368
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986368
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986368
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Specified dose on specified days
Study: NCT04742140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Description: each patient injected 0.5ml in each TrPs of magnesium sulphate according to the treatment group by the same operator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: each patient injected 0.5ml in each TrPs of saline according to the treatment group by the same operator
Study: NCT06201702

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: pomegranate extract
Description: Drink 2 mL of pomegranate extract three times a day for 10 days during the 3 menstrual cycles (from 7 days before to 3 days after the estimated onset of menstruation).
Study: NCT05174260

Intervention type: DEVICE
Intervention: perfusion index, pleth variable index
Description: a clip will be attached to the patient's finger and the perfusion index and pvi will be measured

Intervention type: DEVICE
Intervention: perfusion index, pleth variable index
Description: a clip will be attached to the patient's finger and the perfusion index and pvi will be measured
Study: NCT06463249

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CORE Helpline
Description: All participants will receive the Core Helpline program (CORE) for 2 months, which includes written weight loss material, use of a smartphone app, weekly text messages and email reminders and 1 optional participant-initiated coaching call per month.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CORE Helpline
Description: All participants will receive the Core Helpline program (CORE) for 2 months, which includes written weight loss material, use of a smartphone app, weekly text messages and email reminders and 1 optional participant-initiated coaching call per month.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CORE Helpline
Description: All participants will receive the Core Helpline program (CORE) for 2 months, which includes written weight loss material, use of a smartphone app, weekly text messages and email reminders and 1 optional participant-initiated coaching call per month.
Study: NCT06267716

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PENG block
Description: preoperative ultrasound-guided pericapsular nerve group block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IPB
Description: preoperative ultrasound-guided iliopsoas plane block
Study: NCT05017168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-P63
Description: CT-P63 will be administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching CT-P63
Study: NCT04966715

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epigastric lymph node biopsy
Description: epigastric lymph node biopsy and analysis to evaluate rate dissemination of colorectal carcinomatosis by this way
Study: NCT05379192

Intervention type: OTHER
Intervention: Group 1, Group 2, Group 3, Group 4
Description: The total amount of antiemetic,the time of first antiemetic use and VAS scores at 1, 2, 3, 6, 9, 12, 15, 18, 21 and 24th hours postoperatively will also be recorded according to circadian rhythm

Intervention type: OTHER
Intervention: Group 1, Group 2, Group 3, Group 4
Description: The total amount of antiemetic,the time of first antiemetic use and VAS scores at 1, 2, 3, 6, 9, 12, 15, 18, 21 and 24th hours postoperatively will also be recorded according to circadian rhythm

Intervention type: OTHER
Intervention: Group 1, Group 2, Group 3, Group 4
Description: The total amount of antiemetic,the time of first antiemetic use and VAS scores at 1, 2, 3, 6, 9, 12, 15, 18, 21 and 24th hours postoperatively will also be recorded according to circadian rhythm

Intervention type: OTHER
Intervention: Group 1, Group 2, Group 3, Group 4
Description: The total amount of antiemetic,the time of first antiemetic use and VAS scores at 1, 2, 3, 6, 9, 12, 15, 18, 21 and 24th hours postoperatively will also be recorded according to circadian rhythm
Study: NCT04993755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN-101, 400 mg/day
Description: 400 mg/day of study investigational drug TPN-101 once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
Study: NCT06290531

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flavored Benzocaine topical anesthetic gel 20%
Description: Topical anesthetic gel
Study: NCT05057468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: 2.5-5 mg orally for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 375 mg/ m2 weekly dose for a maximum of 4 weeks
Study: NCT04847739

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Seton Placement
Description: This treatment consists of inserting a seton (a soft flexible tube or nonabsorbable string) into the subject's perianal fistula. The seton will be removed by a study doctor at study visits as applicable.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Seton Placement
Description: This treatment consists of inserting a seton (a soft flexible tube or nonabsorbable string) into the subject's perianal fistula. The seton will be removed by a study doctor at study visits as applicable.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVB-114
Description: AVB-114 consists of stem cells taken from a subject's fat tissue seeded into a bioabsorbable plug. AVB-114 will be inserted into the subject's fistula by a study doctor on Day 0.
Study: NCT05615155

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelets Rich Fibrin (i-PRF / C-PRF)
Description: one site of the mouth will be injected with i-PRF and the other site will be injected with C-PRF
Study: NCT06147128

Intervention type: PROCEDURE
Intervention: Emergency scenario in a simulated setting where open conversion is necessary due to vessel injury during robotic surgery on a dry lab model
Description: Performance of emergency scenario where open conversion is necessary due to vessel injury during robotic surgery on a dry lab model with Da Vinci robotic system
Study: NCT04705428

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FLUORINE VARNISH
Description: Participants in all groups will receive written oral hygiene and oral prophylaxis instructions. All groups will receive the application of fluorine varnish every 3 months.~The application of fluoride in the three groups will be done as follows:~-Drying of the teeth, placement of the fluorine varnish on the teeth by quadrants. The varnish will be left to dry for a few seconds according to the manufacturer's instructions. Children in all groups will be asked to avoid brushing and flossing for one day after applying fluoride. They will be instructed to avoid hard food and hot drinks for 4 hours. Children and parents will be instructed on how to care for their teeth at home: brush teeth with conventional toothpaste containing 1000 ppm sodium fluoride, for 3 minutes without rinsing.~In the following reviews (3 and 6 months) the effectiveness of the treatments will be evaluated by visual examination, tactile examination, fluorescence and photography.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FLUORINE VARNISH
Description: Participants in all groups will receive written oral hygiene and oral prophylaxis instructions. All groups will receive the application of fluorine varnish every 3 months.~The application of fluoride in the three groups will be done as follows:~-Drying of the teeth, placement of the fluorine varnish on the teeth by quadrants. The varnish will be left to dry for a few seconds according to the manufacturer's instructions. Children in all groups will be asked to avoid brushing and flossing for one day after applying fluoride. They will be instructed to avoid hard food and hot drinks for 4 hours. Children and parents will be instructed on how to care for their teeth at home: brush teeth with conventional toothpaste containing 1000 ppm sodium fluoride, for 3 minutes without rinsing.~In the following reviews (3 and 6 months) the effectiveness of the treatments will be evaluated by visual examination, tactile examination, fluorescence and photography.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FLUORINE VARNISH
Description: Participants in all groups will receive written oral hygiene and oral prophylaxis instructions. All groups will receive the application of fluorine varnish every 3 months.~The application of fluoride in the three groups will be done as follows:~-Drying of the teeth, placement of the fluorine varnish on the teeth by quadrants. The varnish will be left to dry for a few seconds according to the manufacturer's instructions. Children in all groups will be asked to avoid brushing and flossing for one day after applying fluoride. They will be instructed to avoid hard food and hot drinks for 4 hours. Children and parents will be instructed on how to care for their teeth at home: brush teeth with conventional toothpaste containing 1000 ppm sodium fluoride, for 3 minutes without rinsing.~In the following reviews (3 and 6 months) the effectiveness of the treatments will be evaluated by visual examination, tactile examination, fluorescence and photography.
Study: NCT06417398

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: T cell injection targeting CD19 chimeric antigen receptor
Description: Intravenous administration, 1 bag each time (depending on individual differences), dose: 1×108-1×109 CD19-CAR-gdT (UTAA09 injection), the investigator can decide whether to reduce or increase the dose and whether multiple infusions are required according to the condition of the subject.
Study: NCT06300320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ05105 tablets
Description: Rovadicitinib (TQ05105) is a novel, oral dual JAK 1/2 and Rho-associated kinases (ROCK) 1/2 inhibitor targeting inflammatory and fibrotic components of cGVHD.
Study: NCT05408585

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regional Anesthesia Techniques
Description: Fascial Plane Blocks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regional Anesthesia Techniques
Description: Fascial Plane Blocks
Study: NCT06147128

Intervention type: PROCEDURE
Intervention: Emergency scenario in a simulated setting where open conversion is necessary due to vessel injury during robotic surgery on a dry lab model
Description: Performance of emergency scenario where open conversion is necessary due to vessel injury during robotic surgery on a dry lab model with Da Vinci robotic system

Intervention type: PROCEDURE
Intervention: Emergency scenario in a simulated setting where open conversion is necessary due to vessel injury during robotic surgery on a dry lab model
Description: Performance of emergency scenario where open conversion is necessary due to vessel injury during robotic surgery on a dry lab model with Da Vinci robotic system

Intervention type: PROCEDURE
Intervention: Emergency scenario in a simulated setting where open conversion is necessary due to vessel injury during robotic surgery on a dry lab model
Description: Performance of emergency scenario where open conversion is necessary due to vessel injury during robotic surgery on a dry lab model with Da Vinci robotic system
Study: NCT06346509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PORT-77
Description: Healthy adult participants will receive a single oral dose of PORT 77.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Healthy adult participants will receive matching placebo on Day 1.
Study: NCT05665335

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renuvion APR System
Description: The treatment area is defined as superior most not to exceed a horizontal line from the superior aspect of the axilla to the midline; inferior most not to cross the junction of the breast with the abdomen (inframammary fold). Lateral border to the outermost curvature of the breast or a vertical line drawn from the preaxillary line to the IMF; medial most to the innermost curvature of the breast up to 1 cm lateral to the sternal midline. The procedure will be in the intradermal and subdermal planes in the full breast area, without penetrating the breast gland.~Renuvion APR System settings will be 60-70% Power, 1.5 LPM, and up to 6 retrograde or 3 antegrade/retrograde passes, with a minimum of 2 incision sites.
Study: NCT05562206

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGMIS (Continuous Glucose Monitoring Infusion Set)
Description: An integrated combination CGM/insulin infusion system